This study was approved by the Research Ethics Review Board on Human Studies of the University of Manitoba (Ethics Reference No. tool for risk stratification and personalized treatment decisions. == Introduction == Monoclonal gammopathies are a heterogeneous group of plasma cell disorders characterized by the proliferation of a single B-cell clone, encompassing malignancies such as multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS), smoldering MM, solitary plasmacytoma, Waldenstrm macroglobulinemia, and osteosclerotic myeloma [1,2]. MM accounts for 13% of all hematological cancers [3,4] and for nearly 2% of deaths from cancer [5]. The incidence rate of MM in the United States is 5.9 of 100,000 [6], whereas in other developed countries, it is 4 of 100,000 [7]. For unknown reasons, myeloma is more common among men than women, and the prevalence in African Americans is two-fold higher than in Caucasian Americans [810]. MGUS is the precursor state of MM[11,12]; the rate of transformation from MGUS to MM is 1% per annum [13]. The cause of progression to MM has remained elusive, although reports have suggested that secondary genetic changes such as N-ras and K-ras mutations [14], altered cytokine profiles, and increased bone marrow (BM) neovascularization based on median microvascular density [15] may play a role. Arecoline Genetic changes frequently occur in MM, which include gross chromosomal rearrangements such as translocations, deletions, duplications, and amplifications of parts of a chromosome or entire chromosomes [1618]. Furthermore, whole genome sequencing of 38 MM tumor genomes revealed changes in histone methylation patterns and mutations in genes involved in the nuclear factor kappa light chain enhancer of activated B cells (NF-B) pathway [19]. Recently, the Multiple Myeloma Research Foundation launched the CoMMpassSMstudy to identify molecular motifs and variations associated with MM [20]. The International Staging System [21] and the Durie Salmon Staging System [18] have been used in staging myeloma; the International Staging System and Durie Salmon Staging System are based on serum markers such as 2-microglobulin, albumin, hemoglobin, calcium, monoclonal proteins, and creatinine, coupled with conventional radiography, computerized tomography, magnetic resonance imaging, and fludeoxyglucose (18F) positron emission tomography/computerized tomography [22]. However, the reliability of these systems is currently under scrutiny [23]. The International Myeloma Working Group has issued guidelines for the clinical risk stratification of patients, which consist of factors such as the type and size of the M protein [24], number of BM plasma cells (BMPCs), constitutional symptoms, Arecoline anemia, hyperviscosity, lymphadenopathy, Ctsd and hepatosplenomegaly [25]. On the other hand, the European System relies on the quantification of plasma cells based on their cluster of differentiation (CD)markers [2632] using flow cytometry [3134]. However, both guidelines are geared toward detecting existing symptoms and thus do not address the unmet need for a reliable method for risk evaluation of patients. Telomeres, the highly repetitive (TTAGGG)nnucleotide sequences situated at the ends of chromosomes, have been strongly associated with tumorigenesis [3540]. Changes in telomere structure result in the formation of aggregates [41], and studies assessing the three-dimensional (3D) nuclear architecture have facilitated monitoring the progression of glioblastoma [42], chronic lymphocytic leukemia [4346], acute myeloid leukemia (AML) [47,48], and Hodgkin lymphoma [49]. Our current study aimed to apply this 3D telomeric structure-based imaging tool for plasma cells from patients with MGUS, MM, and relapsed MM Arecoline (MMrel) to potentially serve as a complementary approach in the design of personalized monitoring regimens and in the assessment of individual risk for MM, MGUS, and MMrel. == Materials and Methods == == Study Population == The study population consisted of a total of 86 patients, which were subdivided into three groups, namely, MM (N= 44), MGUS (N= 27), and MMrel (N= 15). Patient characteristics are presented as Supplementary materials (Table W1). Informed consent was obtained from all patients after a presentation and discussion with a collaborating research nurse from CancerCare Manitoba and Estonia, respectively. This study was approved by the Research Ethics Review Board on Human Studies of the University of Manitoba (Ethics Reference No. H2010:170) and the Ethics Review Committee on Human Research of the University of Tartu (Protocol No. 194T-11). == Isolation of Lymphocytes and Plasma Cells == Lymphocytes from blood samples and BM aspirates were overlaid in Ficoll-Paque (GE Healthcare Life Sciences, Baie d’Urfe, Quebec).